HC Wainwright Has Negative Forecast for uniQure Q2 Earnings

uniQure (NASDAQ:QURE) – Analysts at HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for uniQure in a research note issued on Tuesday, May 13th. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will earn ($0.73) per share for the quarter, down from their previous forecast of ($0.72). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. HC Wainwright also issued estimates for uniQure’s FY2025 earnings at ($3.11) EPS, Q1 2026 earnings at ($0.68) EPS, Q2 2026 earnings at ($0.67) EPS, Q3 2026 earnings at ($0.66) EPS and Q4 2026 earnings at $0.09 EPS.

uniQure (NASDAQ:QURE) last announced its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.25. The firm had revenue of $1.57 million during the quarter, compared to analyst estimates of $5.93 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%.

Other research analysts have also recently issued reports about the stock. Chardan Capital reiterated a “buy” rating and issued a $38.00 target price on shares of uniQure in a research note on Monday. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. Wells Fargo & Company decreased their target price on uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research report on Friday, February 28th. Guggenheim reaffirmed a “buy” rating and set a $28.00 price target on shares of uniQure in a research report on Monday. Finally, StockNews.com raised uniQure to a “sell” rating in a report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.82.

uniQure Price Performance

QURE opened at $13.25 on Friday. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18. The firm has a 50-day moving average of $12.28 and a 200 day moving average of $12.23. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The firm has a market cap of $725.78 million, a P/E ratio of -2.67 and a beta of 0.10.

Institutional Trading of uniQure

Institutional investors and hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. grew its holdings in shares of uniQure by 9.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 969 shares in the last quarter. Tudor Investment Corp ET AL lifted its position in uniQure by 5.9% during the fourth quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company’s stock valued at $438,000 after purchasing an additional 1,371 shares during the last quarter. Wells Fargo & Company MN grew its stake in uniQure by 13.9% in the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock worth $217,000 after buying an additional 1,503 shares in the last quarter. Northern Trust Corp increased its holdings in shares of uniQure by 2.1% in the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock worth $1,688,000 after buying an additional 1,923 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of uniQure by 6.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company’s stock valued at $1,253,000 after buying an additional 3,996 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 28,341 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $291,628.89. Following the completion of the transaction, the chief executive officer now directly owns 651,454 shares in the company, valued at $6,703,461.66. The trade was a 4.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Christian Klemt sold 10,438 shares of the company’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $107,407.02. Following the completion of the transaction, the chief financial officer now directly owns 217,730 shares in the company, valued at approximately $2,240,441.70. The trade was a 4.57% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock worth $961,401 in the last quarter. 4.74% of the stock is owned by company insiders.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.